Literature DB >> 19328839

Differential noxious and motor tolerance of chronic delta opioid receptor agonists in rodents.

H Beaudry1, A Proteau-Gagné, Shuang Li, Y Dory, C Chavkin, L Gendron.   

Abstract

In the present study, we asked whether multiple intrathecal injections of deltorphin II, a selective delta opioid receptor (DOPR) agonist, induced DOPR tolerance in three behavioral assays. Unilateral inflammation caused by complete Freund's adjuvant (CFA) injection into the rat or mouse hind paw (CFA model) induced thermal hyperalgesic response that was transiently and dose-dependently reduced by intrathecal administration of deltorphin II or morphine. In both rodent species, the effect of deltorphin II was not modified by a single prior administration of deltorphin II, suggesting an absence of acute tolerance in this paradigm. Repeated administration of intrathecal deltorphin II or s.c. SB-235863 (five consecutive injections over 60 h) also failed to impair the antihyperalgesic response to delta opioid receptor agonist, whereas repeated intrathecal or s.c. injections of morphine induced a significant decrease in the subsequent thermal antihyperalgesic response to morphine. In mice, deltorphin II also induced a rapid, transient motor incoordination/ataxia-like behavior as tested with the accelerating rotarod. In contrast to the antihyperalgesic responses, tolerance to the motoric effect of deltorphin II was evident in mice previously exposed to multiple intrathecal agonist injections, but not multiple saline administrations. Using the tail flick antinociceptive test, we found that DOPR-mediated analgesia was significantly reduced by repeated exposure to deltorphin II. Altogether, these observations suggest that repeated injections of DOPR agonists induce differential tolerance effects on antihyperalgesic, antinociceptive, and motor incoordination/ataxia-like behaviors related to DOPR activation by deltorphin II.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19328839      PMCID: PMC3727641          DOI: 10.1016/j.neuroscience.2009.03.053

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  66 in total

1.  Effects of multiple intracerebroventricular injections of [D-Pen2,D-Pen5]enkephalin and [D-Ala2,Glu4]deltorphin II on tolerance to their analgesic action and on brain delta-opioid receptors.

Authors:  G M Zhao; H N Bhargava
Journal:  Brain Res       Date:  1997-01-16       Impact factor: 3.252

2.  The role of delta-opioid receptor subtypes in neuropathic pain.

Authors:  J Mika; R Przewłocki; B Przewłocka
Journal:  Eur J Pharmacol       Date:  2001-03-09       Impact factor: 4.432

3.  Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.

Authors:  G Dondio; S Ronzoni; D S Eggleston; M Artico; P Petrillo; G Petrone; L Visentin; C Farina; V Vecchietti; G D Clarke
Journal:  J Med Chem       Date:  1997-09-26       Impact factor: 7.446

4.  Antinociceptive activity of deltorphin analogs in the formalin test.

Authors:  T Chiba; H Murase; A Ambo; Y Sasaki
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

5.  Effects of N-methyl-D-aspartate receptor antagonists on the analgesia and tolerance to D-Ala2, Glu4 deltorphin II, a delta 2-opioid receptor agonist in mice.

Authors:  H N Bhargava; G M Zhao
Journal:  Brain Res       Date:  1996-05-06       Impact factor: 3.252

6.  Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception.

Authors:  C M Cahill; A Morinville; M C Lee; J P Vincent; B Collier; A Beaudet
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

7.  Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidic delta opioid receptor agonist, (-)TAN-67, in the mouse spinal cord.

Authors:  L F Tseng; M Narita; H Mizoguchi; K Kawai; A Mizusuna; J Kamei; T Suzuki; H Nagase
Journal:  J Pharmacol Exp Ther       Date:  1997-02       Impact factor: 4.030

8.  Selective delta opioid receptor agonists for inflammatory and neuropathic pain.

Authors:  G Dondio; S Ronzoni; C Farina; D Graziani; C Parini; P Petrillo; G A Giardina
Journal:  Farmaco       Date:  2001 Jan-Feb

9.  Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).

Authors:  Bertrand Le Bourdonnec; Rolf T Windh; Christopher W Ajello; Lara K Leister; Minghua Gu; Guo-Hua Chu; Paul A Tuthill; William M Barker; Michael Koblish; Daniel D Wiant; Thomas M Graczyk; Serge Belanger; Joel A Cassel; Marina S Feschenko; Bernice L Brogdon; Steven A Smith; David D Christ; Michael J Derelanko; Steve Kutz; Patrick J Little; Robert N DeHaven; Diane L DeHaven-Hudkins; Roland E Dolle
Journal:  J Med Chem       Date:  2008-09-13       Impact factor: 7.446

10.  Tolerance to the antinociceptive effects of peripherally administered opioids. Expression of beta-arrestins.

Authors:  Laura Hernández; Asunción Romero; Pilar Almela; Paula García-Nogales; M Luisa Laorden; Margarita M Puig
Journal:  Brain Res       Date:  2008-11-07       Impact factor: 3.252

View more
  31 in total

Review 1.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches.

Authors:  Claire Gavériaux-Ruff; Brigitte Lina Kieffer
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

3.  Exploring the Backbone of Enkephalins To Adjust Their Pharmacological Profile for the δ-Opioid Receptor.

Authors:  Arnaud Proteau-Gagné; Véronique Bournival; Kristina Rochon; Yves L Dory; Louis Gendron
Journal:  ACS Chem Neurosci       Date:  2010-09-17       Impact factor: 4.418

4.  Endocytic profiles of δ-opioid receptor ligands determine the duration of rapid but not sustained cAMP responses.

Authors:  Hanieh Bagheri Tudashki; Derek N Robertson; Peter W Schiller; Graciela Pineyro
Journal:  Mol Pharmacol       Date:  2013-10-30       Impact factor: 4.436

5.  Spinal μ and δ opioids inhibit both thermal and mechanical pain in rats.

Authors:  Audrey Normandin; Philippe Luccarini; Jean-Louis Molat; Louis Gendron; Radhouane Dallel
Journal:  J Neurosci       Date:  2013-07-10       Impact factor: 6.167

6.  Preparation and evaluation at the delta opioid receptor of a series of linear leu-enkephalin analogues obtained by systematic replacement of the amides.

Authors:  Kristina Rochon; Arnaud Proteau-Gagné; Philippe Bourassa; Jean-François Nadon; Jérome Côté; Véronique Bournival; Fernand Gobeil; Brigitte Guérin; Yves L Dory; Louis Gendron
Journal:  ACS Chem Neurosci       Date:  2013-05-20       Impact factor: 4.418

7.  Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.

Authors:  H Beaudry; L Gendron; J A Morón
Journal:  Eur J Neurosci       Date:  2015-01-09       Impact factor: 3.386

8.  Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.

Authors:  Omar S Mabrouk; Riccardo Viaro; Mattia Volta; Ada Ledonne; Nicola Mercuri; Michele Morari
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

9.  δ-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice.

Authors:  Amynah A Pradhan; Monique L Smith; Jekaterina Zyuzin; Andrew Charles
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

10.  Kappa Opioid Receptor-Mediated Disruption of Novel Object Recognition: Relevance for Psychostimulant Treatment.

Authors:  Jason J Paris; Kate J Reilley; Jay P McLaughlin
Journal:  J Addict Res Ther       Date:  2011-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.